| General Information | |
|---|---|
| ZINC ID | ZINC000096938078 |
| Molecular Weight (Da) | 341 |
| SMILES | CCCCCn1c2ccccc2c2cc(C(=O)c3ccccc3)ccc21 |
| Molecular Formula | C24N1O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 105.05 |
| HBA | 1 |
| HBD | 0 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 26 |
| LogP | 6.628 |
| Activity (Ki) in nM | 288.403 |
| Polar Surface Area (PSA) | 22 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | - |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.21212983 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 19 |
| Fraction csp3 | 0.21 |
| Ilogp | 3.79 |
| Xlogp3 | 7.26 |
| Wlogp | 6.22 |
| Mlogp | 4.46 |
| Silicos-it log p | 6 |
| Consensus log p | 5.54 |
| Esol log s | -6.68 |
| Esol solubility (mg/ml) | 0.0000721 |
| Esol solubility (mol/l) | 0.00000021 |
| Esol class | Poorly sol |
| Ali log s | -7.55 |
| Ali solubility (mg/ml) | 0.00000969 |
| Ali solubility (mol/l) | 2.84E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.57 |
| Silicos-it solubility (mg/ml) | 0.00000091 |
| Silicos-it solubility (mol/l) | 2.69E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.23 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 2.23 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.353 |
| Logd | 4.733 |
| Logp | 6.173 |
| F (20%) | 0.87 |
| F (30%) | 0.994 |
| Mdck | - |
| Ppb | 99.53% |
| Vdss | 1.023 |
| Fu | 0.51% |
| Cyp1a2-inh | 0.903 |
| Cyp1a2-sub | 0.205 |
| Cyp2c19-inh | 0.856 |
| Cyp2c19-sub | 0.063 |
| Cl | 2.602 |
| T12 | 0.062 |
| H-ht | 0.067 |
| Dili | 0.932 |
| Roa | 0.118 |
| Fdamdd | 0.922 |
| Skinsen | 0.166 |
| Ec | 0.003 |
| Ei | 0.902 |
| Respiratory | 0.21 |
| Bcf | 2.617 |
| Igc50 | 5.405 |
| Lc50 | 6.219 |
| Lc50dm | 6.095 |
| Nr-ar | 0.036 |
| Nr-ar-lbd | 0.013 |
| Nr-ahr | 0.816 |
| Nr-aromatase | 0.821 |
| Nr-er | 0.917 |
| Nr-er-lbd | 0.864 |
| Nr-ppar-gamma | 0.01 |
| Sr-are | 0.876 |
| Sr-atad5 | 0.682 |
| Sr-hse | 0.104 |
| Sr-mmp | 0.888 |
| Sr-p53 | 0.821 |
| Vol | 382.857 |
| Dense | 0.891 |
| Flex | 0.273 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 3 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.301 |
| Synth | 1.875 |
| Fsp3 | 0.208 |
| Mce-18 | 20 |
| Natural product-likeness | -0.568 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |